An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

This publication has 47 references indexed in Scilit:

• Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril), and tropisetron (navoban)
  Cancer, 1995
• The 5-hydroxytryptamine receptor antagonists as antiemetics: Preclinical evaluation and mechanism of action
  European Journal Of Cancer, 1993
• Urinary serotonin metabolite excretion during cisplatin chemotherapy
  Cancer, 1993
• Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of Antiemetics
  The Journal of Clinical Pharmacology, 1993
• Are all 5-HT3 receptor antagonists the same?
  European Journal Of Cancer, 1992
• Review paper
  Anti-Cancer Drugs, 1992
• Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting
  New England Journal of Medicine, 1990
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial
  Cancer, 1987
• Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism
  British Journal of Pharmacology, 1986
• Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
  New England Journal of Medicine, 1981